Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

Bone Marrow Transplantation

Volumn 35, Issue 3, 2005, Pages 233-241

  Beelen, Dietrich W ^a   Trenschel, R ^a   Casper, J ^b   Freund, M ^b   Hilger, R A ^a   Scheulen, M E ^a   Basara, N ^c   Fauser, A A ^c   Hertenstein, B ^d   Mylius, H A ^e   Baumgart, J ^e   Pichlmeier, U ^e   Hahn, J R ^f   Holler, E ^f  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c Department of Haematology/Oncology   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MEDAC GMBH   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Allogeneic; Conditioning; Pharmacokinetic; Transplantation; Treosulphan

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DONOR; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG URINE LEVEL; ESOPHAGITIS; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY FAILURE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG ALVEOLITIS; LUNG INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SEIZURE; THROMBOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PHARMACOKINETICS; RECURRENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 13944280315     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704784     Document Type: Article

References (26)

1. Harstrick A, Wilke H, Eberhardt W et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996; 19: 153-156.
2. Scheulen ME, Hilger RA, Oberhoff C et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209-4216.
3. Baynes RD, Dansey RD, Klein JL et al. A phase I trial of escalating treosulfan in combination with high-dose melphalan and dacarbazine (TMD) with peripheral blood progenitor cell transplant (PBPCT) in recurrent metastatic ovarian and breast cancer. Blood 2000; 96: 170a (Abstr. 731).
4. Westerhof GR, Ploemacher RE, Boudewijn A et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470-5478.
5. Ploemacher RE, Westerhof GR, Blokland I et al. Treosulfan as an alternative conditioning agent in bone marrow transplantation. Bone Marrow Transplant 2000; 25 (Suppl. 1) (Abstr. P421).
6. Ploemacher RE, Johnson KW, Rombouts EJC et al. Addition of treosulfan in a non-myeloablative conditioning regimen results in enhanced chimerism and immunological tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 236-245.
7. van Pel M, van Breugel DWJG, Vos W et al. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC-barriers. Bone Marrow Transplant 2003; 32: 15-22.
8. Andersson G, Illigens BMW, Johnson KW et al. Non-myeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 2003; 101: 4305-4312.
9. Van Pel M, van Breugel DWJG, Vos W et al. Towards a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. Bone Marrow Transplant 2004; 33: 1-7.
10. Meinhardt G, Dayyani F, Jahrsdörfer B et al. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Hematol 2003; 122 1-8.
11. Schmidmaier R, Oellerich M, Baumgart J et al. Treosulfan induced apoptosis in AML cells is accompanied by translocation of PKC delta and enhanced by Bryostatin-1. Exp Hematol 2004; 32 76-86.
12. Topaly J, Fruehauf S, Ho AD, Zeller WJ. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 2002; 86: 1487-1493.
13. Fichtner I, Becker M, Baumgart J. Antileukemic activity of treosulfan in xenografted human acute lymphoblastic leukemias (ALL). Eur J Cancer 2003; 39: 801-807.
14. Weissert R, Wiendl H, Pfrommer H et al. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalo-myelitis and human lymphocytes. J Neuroimmunol 2003; 144: 28-37.
15. Casper J, Knauf W, Kiefer T et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic blood stem cell transplantation. Blood 2004; 103: 725-731.
16. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Hilger RA, Harstrick A, Eberhardt W et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998; 42: 99-104.
18. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data, 2nd edn. Statistics for Biology and Health, Springer: Berlin, 2003.
19. Heinzel G, Woloszczak R, Thomann P. TOPFIT Version 2.0. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Fischer/VCH: Stuttgart, 1993.
20. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
21. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231-234.
22. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
23. McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
24. Hassan M, Ljungman P, Ringdén O et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924.
25. Hartman A-R, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22 439-443.
26. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.